The global oral mucositis drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of oral mucositis in cancer patients undergoing chemotherapy and radiotherapy, which is driving the demand for these drugs.
Mouthwash: The mouthwash segment accounted for the largest share in 2018 and it is expected to continue its dominance throughout the forecast period. Mouthwashes are used as an adjunct therapy for preventing or reducing oral mucositis symptoms such as pain, dryness, ulceration, and bleeding. Mouthwashes are also used as a preventive measure against oral mucositis caused by chemotherapy or radiotherapy treatment.
Mouthwashes can be classified into two types: antiseptic mouthwashes that contain alcohols such as chlorhexidine gluconate (CHX) or cetylpyridinium chloride (CPC), and non-antiseptic mouthwashes that do not contain alcohols but have other active ingredients such as sucralfate (a protective agent), sodium bicarbonate (a buffer), potassium nitrate (an anti-inflammatory agent), zinc sulfate (an astringent) etc, which help reduce inflammation in tissues lining the mouth cavity and prevent ulcers from developing on these tissues due to radiation therapy or chemotherapy treatments.
Pain Control Medication: Pain control medication accounted for a small share in 2018 but it is expected to grow at a CAGR of 8% during 2020-2030 owing to increasing prevalence of pain among cancer patients undergoing chemotherapy or radiotherapy treatment due to increased severity of side effects like nausea, vomiting, diarrhea etc, which leads them towards using pain control medications more often than before. Pain control medications can be classified into two types: analgesics that relieve pain by blocking nerve impulses from reaching brain; non-steroidal anti-inflammatory drugs that reduce inflammation by inhibiting cyclooxygenase enzymes responsible for production of prostaglandins; opioids that relieve severe pain by binding with opioid receptors present on nerve cells; antidepressants like amitriptyline hydrochloride      that block reuptake of serotonin thereby relieving depression related symptoms like anxiety etc; antipsychotics like risperidone hydrochloride that blocks dopamine receptors thereby relieving psychotic symptoms like delusions etc; anticonvulsants like carbamazepine sodium tablets/capsules/oral suspension/oral solution/tablets containing enteric coated pellets/tablets containing enteric coated granules/tablets containing enteric coated beads which prevent seizures by blocking voltage gated sodium channels present on nerve cells; benzodiazepines such as clonazepam tablets which relieve anxiety related symptoms caused due to stress induced conditions through their action on GABA receptors present on nerve cells; muscle relaxants such as diazepam tablets which relieve muscle spasms through their action on GABA receptors present on nerve cells; sedatives such as lorazepam tablets which induce sleepiness through their action on GABA receptors present on nerve cells; antidepressants including amitriptyline hydrochloride tablets / capsules / oral suspension / oral solution / tablets containing enteric coated pellets / tables containing enteric coated granules / tables containing enteric coated beads ; antipsychotics including risperidone hydrochloride tablet ; anticonvulsants including carbamazepine sodium tablet ; benzodiazepines including clonazepam tablet ; muscle relaxants including diazepam tablet ; sedatives including lorazepam tablet.
-The global Oral Mucositis Drugs market is expected to grow at a CAGR of XX% during the forecast period.
-The increasing prevalence of oral mucositis in cancer patients is one of the major factors driving the growth of this market.
-Increasing incidence rates for oral mucositis in HIV/AIDS patients and other chronic diseases are also driving the growth of this market.
-Increasing awareness about oral mucositis among physicians and healthcare professionals is also expected to drive the growth of this market.
-The introduction and approval by regulatory authorities for new drugs are some other factors that are expected to drive the growth of this market.
Industry Growth Insights published a new data on “Oral Mucositis Drugs Market”. The research report is titled “Oral Mucositis Drugs Market research by Types (Mouthwash, Pain Control Medication, Other), By Applications (Chemotherapy, Radiotherapy), By Players/Companies 3M Healthcare, GSK, Pfizer, Colgate-Palmolive, Norgine, Biovitrum , Valeant Pharmaceuticals, EUSA Pharma, Camurus, Mission Pharmacal, Clinigen Group, Midatech Pharma, Alliance Pharma, AMAG Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Mucositis Drugs Market Research Report
By Type
Mouthwash, Pain Control Medication, Other
By Application
Chemotherapy, Radiotherapy
By Companies
3M Healthcare, GSK, Pfizer, Colgate-Palmolive, Norgine, Biovitrum , Valeant Pharmaceuticals, EUSA Pharma, Camurus, Mission Pharmacal, Clinigen Group, Midatech Pharma, Alliance Pharma, AMAG Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Oral Mucositis Drugs Market Report Segments:
The global Oral Mucositis Drugs market is segmented on the basis of:
Types
Mouthwash, Pain Control Medication, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chemotherapy, Radiotherapy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 3M Healthcare
- GSK
- Pfizer
- Colgate-Palmolive
- Norgine
- BiovitrumÂ
- Valeant Pharmaceuticals
- EUSAÂ Pharma
- Camurus
- Mission Pharmacal
- Clinigen Group
- Midatech Pharma
- Alliance Pharma
- AMAG Pharmaceuticals
Highlights of The Oral Mucositis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Mouthwash
- Pain Control Medication
- Other
- By Application:
- Chemotherapy
- Radiotherapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Mucositis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral mucositis drugs are medications that help to relieve symptoms of oral mucositis, such as pain, swelling, and difficulty swallowing. These drugs can be prescribed by a doctor or obtained over the counter. Some common oral mucositis drugs include ibuprofen (Advil, Motrin), naproxen (Aleve), and diclofenac (Voltaren).
Some of the key players operating in the oral mucositis drugs market are 3M Healthcare, GSK, Pfizer, Colgate-Palmolive, Norgine, Biovitrum‚Â , Valeant Pharmaceuticals, EUSA‚Â Pharma, Camurus, Mission Pharmacal, Clinigen Group, Midatech Pharma, Alliance Pharma, AMAG Pharmaceuticals.
The oral mucositis drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oral Mucositis Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oral Mucositis Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oral Mucositis Drugs Market - Supply Chain
4.5. Global Oral Mucositis Drugs Market Forecast
4.5.1. Oral Mucositis Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oral Mucositis Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oral Mucositis Drugs Market Absolute $ Opportunity
5. Global Oral Mucositis Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oral Mucositis Drugs Market Size and Volume Forecast by Type
5.3.1. Mouthwash
5.3.2. Pain Control Medication
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oral Mucositis Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oral Mucositis Drugs Market Size and Volume Forecast by Application
6.3.1. Chemotherapy
6.3.2. Radiotherapy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oral Mucositis Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oral Mucositis Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oral Mucositis Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oral Mucositis Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oral Mucositis Drugs Demand Share Forecast, 2019-2029
9. North America Oral Mucositis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oral Mucositis Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oral Mucositis Drugs Market Size and Volume Forecast by Application
9.4.1. Chemotherapy
9.4.2. Radiotherapy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oral Mucositis Drugs Market Size and Volume Forecast by Type
9.7.1. Mouthwash
9.7.2. Pain Control Medication
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oral Mucositis Drugs Demand Share Forecast, 2019-2029
10. Latin America Oral Mucositis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oral Mucositis Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oral Mucositis Drugs Market Size and Volume Forecast by Application
10.4.1. Chemotherapy
10.4.2. Radiotherapy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oral Mucositis Drugs Market Size and Volume Forecast by Type
10.7.1. Mouthwash
10.7.2. Pain Control Medication
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oral Mucositis Drugs Demand Share Forecast, 2019-2029
11. Europe Oral Mucositis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oral Mucositis Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oral Mucositis Drugs Market Size and Volume Forecast by Application
11.4.1. Chemotherapy
11.4.2. Radiotherapy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oral Mucositis Drugs Market Size and Volume Forecast by Type
11.7.1. Mouthwash
11.7.2. Pain Control Medication
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oral Mucositis Drugs Demand Share, 2019-2029
12. Asia Pacific Oral Mucositis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oral Mucositis Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oral Mucositis Drugs Market Size and Volume Forecast by Application
12.4.1. Chemotherapy
12.4.2. Radiotherapy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oral Mucositis Drugs Market Size and Volume Forecast by Type
12.7.1. Mouthwash
12.7.2. Pain Control Medication
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oral Mucositis Drugs Demand Share, 2019-2029
13. Middle East & Africa Oral Mucositis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oral Mucositis Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oral Mucositis Drugs Market Size and Volume Forecast by Application
13.4.1. Chemotherapy
13.4.2. Radiotherapy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oral Mucositis Drugs Market Size and Volume Forecast by Type
13.7.1. Mouthwash
13.7.2. Pain Control Medication
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oral Mucositis Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Oral Mucositis Drugs Market: Market Share Analysis
14.2. Oral Mucositis Drugs Distributors and Customers
14.3. Oral Mucositis Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. 3M Healthcare
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Colgate-Palmolive
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Norgine
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biovitrum
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Valeant Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. EUSA Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Camurus
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mission Pharmacal
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Clinigen Group
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Midatech Pharma
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Alliance Pharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. AMAG Pharmaceuticals
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
